Are coagulation times biomarkers? Data from a phase I study of the oral thrombin inhibitor LB-30057 (CI-1028)

Journal of Clinical Pharmacology

Volumn 43, Issue 2, 2003, Pages 118-121

  Stern, Ralph ^a   Chanoine, Francoise ^a   Criswell, Kay ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECARIN; LB 30057; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; BENZAMIDES; BIOLOGICAL MARKERS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE;

EID: 0037303564     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002239818     Document Type: Article

References (11)

1. Oh YS, Yun M, Hwang SY, Hong S, Shin Y, Lee K, et al: Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor. Bioorg Med Chem Lett 1998;8:631-634.
2. McClanahan T, Hicks GW, Ignasiak DP, Bousley R, Mertz TE, Juneau P, et al: The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis. J Thrombosis Thrombolysis 2000;10:277-284.
3. Chi L, Mertz TE, Rogers KL, Janiczek N, Peng Y-W, Saganek L, et al: Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran. J Thrombosis Thrombolysis 2001;11:19-32.
4. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints; preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
5. Lee JW, Hulse JD, Colburn WA: Surrogate biochemical markers: precise measurement for strategic drug and biologics development. J Clin Pharmacol 1995;35:464-470.
6. Nowak G: Clinical monitoring of hirudin and direct thrombin inhibitors. Sem Thromb Hemost 2001;27:537-541.
7. Moser M, Ruef J, Peter K, Kohler B, Gulba DC, Paterna N, et al: Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. J Thrombosis Thrombolysis 2001;12:165-169.
8. Potzsch B, Hund S, Madlener K, Unkrig C, Muller-Berghaus G: Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997;86:373-383.
9. Markwardt F, Nowak G, Sturzebecher J, Griessbach U, Walsmann P, Vogel G: Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemostas 1984;52:160-163.
10. Garrigou D, Dubruc C, Thuillez C, Bergougnan L, Thenot JP: PK-PD relationship of the effects of argatroban on haemostasis in healthy young volunteers. Clin Pharmacol Ther 1999;65:151.
11. Gaussem P, Dubar M, le Bonniec B, Richard-Lordereau I, Jochemsen R, Aich M: Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S18326 in healthy subjects. Br J Clin Pharmacol 2002;53:147-154.